ImPact Biotech Presents Updated Efficacy Data from Evaluation of Padeliporfin VTP in LG UTUC and IntermediateRisk Prostate Cancer at AUA 2025
– Complete response (CR) observed in 79% (26/33) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase (ITP) of the ENLIGHTED Phase 3 trial evaluating Padeliporfin VTP in UTUC – – Padeliporfin VTP treatment continues to be safe and efficacious, establishing profile consistent with prior results alongside additional … Continued
ImPact Biotech Announces New Data Presentations at AUA 2025 Highlighting Safety and Efficacy of Padeliporfin VTP
Company to present updated preliminary results from ENLIGHTED Phase 3 Study in LG UTUC Additional podium presentation to provide updates from long-term evaluation of Padelipor n VTP in intermediate-risk prostate cancer TEL AVIV, Israel, April 11, 2025 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology company focused on developing Padelipor n vascular targeted photodynamic (VTP) … Continued
ImPact Biotech Presents Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at SUO 2024
Complete response (CR) observed in 85% (17/20) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase Padeliporfin VTP treatment continues to be safe and efficacious, establishing profile consistent with prior results alongside additional follow-up in Maintenance Treatment Phase TEL AVIV, Israel, Dec. 04, 2024 (GLOBE NEWSWIRE) — ImPact … Continued
ImPact Biotech Presents Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin n VTP in Low Grade UTUC at EMUC 2024
Complete response (CR) observed in 86% (12/14) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase Padeliporfin VTP treatment continues to be safe and efficacious, establishing profile consistent with prior results alongside additional follow-up in Maintenance Treatment Phase TEL AVIV, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) — ImPact … Continued
ImPact Biotech to Present Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at EMUC 2024
TEL AVIV, Israel, Oct. 25, 2024 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporn vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced an abstract including interim results from ENLIGHTED, the Company’s ongoing Phase 3 study of Padeliporn VTP treatment of patients with low-grade upper … Continued